Kiran Mazumdar-Shaw is the founder of Biocon, one of India’s well-known biotechnology companies. She started Biocon at a time when biotechnology was still a new field in India.
Starting a business was not easy for her. She had limited money, limited resources and very few people understood the kind of work she wanted to do.
She started Biocon in 1978 from a small rented space in Bengaluru. Over the years, the company grew from a small business into a large biotechnology and pharmaceutical company.
Her journey is closely connected with the growth of India’s biotechnology industry.
Early Life and Education
Kiran Mazumdar-Shaw was born on March 23, 1953, in Bengaluru.
Her father, Rasendra Mazumdar, worked as a head brewmaster at United Breweries. Because of her father’s work, Kiran became interested in fermentation and brewing at an early age.
She studied at Bishop Cotton Girls’ High School in Bengaluru and later at Mount Carmel College.
She wanted to become a doctor, but later chose to study biology.
She completed her bachelor’s degree in Zoology from Bangalore University in 1973.
After this, she went to Australia to study malting and brewing. She studied at the University of Melbourne and completed a master’s degree in brewing and malting.
She returned to India with training in a field that was not very common for women at that time.
Starting Her Career
After returning to India, Kiran Mazumdar-Shaw wanted to work as a brewmaster.
However, she faced problems finding a job in India.
Brewing was mainly a male-dominated industry. Some companies were not willing to hire a woman for a senior technical position.
This was a difficult period for her.
Instead of giving up, she started looking for other opportunities where she could use her knowledge of fermentation.
This eventually led her toward biotechnology.
Starting Biocon
In 1978, Kiran Mazumdar-Shaw started Biocon India.
She started the company in a small rented garage in Bengaluru.
The beginning was not easy.
She had only a small amount of money to start the business. Banks were also not very comfortable giving loans to a young woman starting a biotechnology company.
Finding employees was another problem.
At that time, biotechnology was not a large industry in India. There were not many people with the right skills and experience.
Kiran started with a very small team.
The company’s first products were enzymes used in industries such as food, textiles and brewing.
These products gave Biocon a starting point in the biotechnology business.
Growing the Business
Biocon slowly expanded its work.
The company started producing more industrial enzymes and entered international markets.
Its products were used by companies in different countries.
This helped Biocon gain experience in research, manufacturing and international business.
Over time, the company moved from making industrial enzymes to more advanced biotechnology products.
This was a major change in its business.
Moving Into Healthcare
Biocon later began focusing more on healthcare and pharmaceuticals.
The company invested in research and development.
It started working on products related to diabetes, cancer and other serious health conditions.
Biocon also developed expertise in biologics and biosimilars.
These medicines are complex products that require advanced research and manufacturing facilities.
The shift toward healthcare helped Biocon move into a much larger market.
Biocon’s Focus on Insulin
Diabetes became one of the important areas for Biocon.
The company developed and manufactured insulin products.
Biocon worked to make insulin and other diabetes treatments more affordable.
The company also developed other products for chronic diseases.
This became an important part of its healthcare business.
Biocon’s International Growth
Biocon did not limit its business to India.
The company started working with international companies and entered markets outside India.
Partnerships became an important part of this growth.
Biocon worked with companies in different countries to develop and sell pharmaceutical products.
The company also expanded its research and manufacturing capabilities.
This helped Biocon become known as an Indian company with a global biotechnology business.
Biocon’s IPO
Another important stage in Biocon’s journey came in 2004.
Biocon became a publicly listed company in India.
Its initial public offering, or IPO, attracted strong interest.
The listing gave Biocon access to public capital and increased its visibility.
It also showed that an Indian biotechnology company could build a large business and enter the stock market.
Biocon Biologics
Biocon later created Biocon Biologics as a specialised business focused on biosimilars.
Biosimilars are medicines that are highly similar to already approved biological medicines.
This became an important area of growth for the company.
Biocon Biologics expanded through partnerships and acquisitions.
One major development came in 2022 when Biocon Biologics completed the acquisition of the biosimilars business of Viatris.
The deal significantly increased Biocon’s presence in global biosimilars.
Challenges Faced by Kiran Mazumdar-Shaw
Kiran Mazumdar-Shaw faced many challenges during her journey.
When she started Biocon, biotechnology was still a new industry in India.
There was limited funding and limited infrastructure.
She also faced gender-related barriers.
People sometimes doubted her because she was a young woman starting a technical business.
Building trust with banks, employees and customers took time.
The pharmaceutical and biotechnology industries also require large investments in research and development.
Products can take years to develop and get regulatory approval.
Biocon had to spend money and time before some products could reach the market.
Research and Development
Research has always been an important part of Biocon’s business.
The company invests in developing new medicines and improving existing treatments.
Biotechnology is a field where companies need strong research teams and modern facilities.
Biocon built research centres and manufacturing facilities to support its work.
The company also worked with universities, research organisations and international companies.
Kiran Mazumdar-Shaw’s Leadership
Kiran Mazumdar-Shaw has remained closely associated with Biocon since its beginning.
She helped build the company over several decades.
Her approach focused on research, science and long-term growth.
She also believed that healthcare products should be available at reasonable prices.
Under her leadership, Biocon moved from industrial enzymes into pharmaceuticals, biologics and biosimilars.
This change took many years and required large investments.
Biocon Beyond India
Biocon’s business now has a strong international presence.
Its products and medicines reach markets outside India.
The company works in areas such as diabetes, cancer, immunology and other chronic diseases.
Its biosimilars business has become an important part of its international operations.
Biocon has also developed partnerships with global pharmaceutical companies.
These partnerships have helped the company enter new markets and bring its products to more patients.
Biocon Today
Biocon has grown far beyond the small company that Kiran Mazumdar-Shaw started in 1978.
The Biocon Group now has businesses covering biopharmaceuticals, biosimilars and other healthcare products.
Biocon Limited is based in Bengaluru.
Biocon Biologics is a major part of the group’s global biosimilars business.
The company continues to work on medicines for serious health conditions and invests in research and development.
Conclusion
Kiran Mazumdar-Shaw started Biocon in 1978 with a small team and limited resources.
At that time, biotechnology was not a well-established industry in India.
She faced problems with funding, hiring and finding acceptance in a male-dominated business environment.
But she continued to build the company step by step.
Biocon first worked with industrial enzymes and later moved into healthcare and pharmaceuticals. The company then expanded into biologics and biosimilars.
Today, Biocon is known as one of India’s important biotechnology companies.
Kiran Mazumdar-Shaw’s business journey shows how a small idea can grow over many years when a founder stays focused on the work and is willing to learn and change with the industry.
